OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today at the 29th www.intensive.org (ISICEM) in Brussels, Belgium, that it has received a European CE Mark (Conformité Européenne) approval for its NBM-200MP, a multi-parameter sensor for non-invasive continuous hemoglobin, low signal oximetry and pulse rate measurements.
“We are excited about receiving the European CE approval for NBM-200MP. This is an important milestone for OrSense in the path for developing and marketing our unique non-invasive multi-parameter blood monitoring device, which is expected to enhance the quality of treatment and reduce operational costs in hospitals,” said Lior Ma’ayan, CEO of OrSense. “Upon receiving the CE mark, we will soon initiate sales in various counties in Europe.”
The Company is holding a symposium that will be chaired by Professor Pierre Singer, MD, Head of the Intensive Care Department, Rabin Medical Center, Petah-Tikva, Israel and Sackler School of Medicine, Tel Aviv University, who will present new data indicating that OrSense’s non-invasive continuous monitoring system accurately measures levels of oxygen saturation, hemoglobin and glucose in an intensive care unit.
Hemoglobin (Hb) level, a parameter which indicates hemorrhage or anemia, is a key measurement in hospitals and outpatient wards. However, current hemoglobin measurements are invasive, time consuming, labor intensive and costly. Non-invasive pulse oximetry has become a standard of care throughout the medical world, yet it has been known to provide erroneous oxygen saturation readings in states of low perfusion, low cardiac output and/or low blood flow. The NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation under all physiological conditions, as well as a unique, breakthrough non-invasive solution for accurate continuous and spot Hb measurements.
Source: OrSense
